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Abstract
A series of Pt(ll) complexes with antitumor properties: [1,2-bis(2,6-dichloro-4-
hydroxyphenyl)ethylenediamine]PtL2 (meso-l-PtL2) and [erythro-l-(2,6-dichloro-4-hydroxyphenyl)-
2-(2-halo-4-hydroxyphenyl)ethylenediamine]PtL2, [2L 2C1-, 21-, SO42"; halo F (erythro-8-PtL2),
halo = CI (erythro-9-PtL2)] has been modelled by molecular mechanics (MM). The MM calculations
were carried out for different isomers and ligand conformations meso-5, meso-X, d,l-5, d,I-X. The
compounds with the lowest MM energies have the same geometries as those obtained by X-ray
analysis. The calculated MMX energy orders: meso-l-PtL2 < erythro-9-PtL2 < erythro-8-PtL2 for L
I-, CI- and SO42- are reverse to the known antitumor activity order- the lowest energy complex
(the most stable one)is the one with the highest estrogen activity (meso-l-PtL2). The type of the
leaving group (L) does not alter the energy order, which is in agreement with the biological
experiments that show a slight dependence of the estrogen properties on the leaving group type.
Introduction
The coordination compounds of Pt(ll) are among the most important antitumor reagents.
Cis-Pt(NH3)2CI2(cisplatin) was the first platinum compound tested on a wide scale for cytostatic
effects [1-4]. This compound, however, is toxic and in some cases not selective enough [5]. A new
class of Pt(ll) compounds, designed by combining the cytotoxic PtCI2 group (the active moiety in
cisplatin) and a diamine ligand with estrogen-receptor affinity has been found [6-9]. These new
complexes retain the estrogen properties of the ligand that binds to the estrogen receptor which is
specific for the tumor cell and thus the complexes attack selectively critical areas of the DNA [9-
15]. Such compounds are more selective and less toxic [6]. The synthetic estrogen, hexestrol
(HES-nonsteroidal) (Fig. 1) has been used as a model of a ligand with estrogen-receptor affinity
[7]. By exchange of the ethyl side chains with amino groups, HES was transformed into a
compound suitable for coordination to Pt(ll) (Fig. 1). After this structural modification, however,
HES loses its high affinity to the estrogen receptor as well as its marked estrogen activity [17]. To
increase the lipophilic character of the diamine, two chlorine atoms have been introduced into 2-
and 6-positions of the aromatic rings [18]. The compound thus obtained (meso-1) as well as its
dichloroplatinum(ll) complex (meso-l-PtCI2) proved to be "true" estrogens [9].
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Fig. 1. Transformation of Hexestrol (HES) into a Pt(ll) complex with estrogen activity (meso-1-
PtCl2) [7].
The compounds [meso-l,2-bis(2,6-dichloro-4-hydroxyphenyl) ethylene-diamine] PtL2
(meso-l-PtL2) and [erythro-l-(2,6-dichloro-4-hydroxyphenyl)-2-(2-halo-4-hydroxyphenyl)
ethylenediamine]PtL2 [2L = 2C1-, 21-, SO42-; halo = F (erythro-8-PtL2), halo = CI (erythro-9-PtL2)]
have been found to possess estrogen properties and have been tested as antitumor agents [9,12-
22]. The compounds show different estrogen activity [12]. The type (CI, F, H, OH) and the positions
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(ortho-, meta-, para-) of the substituents in the aromatic rings strongly influence their estrogen
properties [10,12,15]. At the same time the type of the leaving group (CI-, I-, SO42-) was of minor
importance for the estrogen activity [18].
The stability of the studied Pt(ll) compounds, used as antitumor agents is important for the
transport of the complex to the estrogen receptor. The more stable complex will reach the specific
estrogen receptor of the tumor cell in higher concentration [23].
Recently, we have showed [24,25] that the thermodynamic stability correlates with the rate
of hydrolysis of d,I- and meso-[1,2 bis (2-hydroxyphenyl) ethylenediamine] dichloroplatinum(ll) (3-
PtCI2). Among the studied isomers the lowest energy one, d,I-X shows the highest rate of
hydrolysis and highest antitumor activity.
In another theoretical study we have shown that the type and the positions of the ring
substituents alter the calculated conformational energies (thermodynamic stabilities) of the studied
compounds in agreement with their antitumor activity [26].
The geometry of the active compounds is also important since it will define the bonding
mode to the estrogen receptor. Both factors thermodynamic stability and geometry cannot be
taken from crystal structures since these factors for the compounds in solutions may differ
substantially. The molecular structure and thermodynamic stability, however, can readily be
approached by molecular modelling.
The purpose of the present work is to examine all possible isomers of the compounds
mentioned above, using molecular mechanics. Correlations between the calculated MM energies
(thermodynamic stabilities) and the known estrogen activity order are expected to be found.
Different leaving groups, (CI-, I-, SO42-) were used in the calculations in order to study the
influence of the leaving group, L, on the calculated energies and stabilities.
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Fig. 2. Different conformations of the meso-l-PtL2 (X=Y=CI, Z=OH), erythro-5-PtL2 (X=Y=H,
Z=OH), erythro-7-PtL2 (X=Y=CI, Z=H), erythro-8-PtL2 (X=F, Y=H, Z=OH) and erythro-9-PtL2 (X=CI,
Y=H, Z=OH).
92Natasha Trendafilova et al. Metal Based Drugs
Methods
Molecular Mechanics is now a well-established technique in the field of inorganic
chemistry. It was successfully applied to many coordination compounds to predict and rationalize
the conformational behaviour of different metal complexes [27-36]. This approach was successfully
applied also for modelling of a number of Pt(ll) compound used as anticancer drugs [37].
We have used the standard MMX (an enhanced version of MMP2) procedure with the
parameters collected in its 1988 version [38] (see Appendix). The calculated MM energies are
used to access the relative stability of the studied complexes as suggested elsewhere [39].
In some cases, namely for cisplatin and its substituted ethylenediamine derivative, MM
calculations, which ignore explicitly the electronic factors, gave lower energies for the tetrahedral
structures than for the planar ones [24]. To calculate the geometry of the higher energy square-
planar structures by the MM method in such cases we fixed the ligand donor atoms in a plane.
Results and Discussion
The studied complexes are given in Fig. 2 and Fig. 3:
For the complexes shown in the two Figures the following isomers have been studied:
(i) four meso isomers (one aromatic ring is in axial- and the second in equatorial
orientations): among them, two 5 conformers, (Fig. 2a and 2c) and two X conformers (Fig. 2b and
2d);
(ii) one d,I isomer, 5 conformer (both aromatic rings are in axial orientations) (Fig. 3a).
(iii) one d,I isomer, , conformer (both aromatic rings are in equatorial orientations) (Fig.
3b).
We shall now examine the influence of A. the type of the leaving group (L), B. ring
substituents (X, Y and Z) and C. rotational barriers about Csp3- Car bond.
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Fig. 3. Different conformations of the d,l-l-PtL2 (X=Y=CI, Z=OH), threo-5-PtL2 (X=Y=H, Z=OH),
threo-7-PtL2 (X=Y=CI, Z=H), threo-8-PtL2 (X=F, Y=H, Z=OH) and threo-9-PtL2 (X=CI, Y=H,
Z=OH).
A. Influence of the type of the leaving group on the conformational energies
The MM energies of the studied compounds were calculated in the presence of three
different leaving groups: L = I-, CI- and SO42-. The MM calculations showed that the main
contribution to the calculated energy comes from the stretching energy term. Small variations of
the Pt-L bond lengths in the Ptl2 complexes produce large energy changes. To estimate the
correlation E vs. r(Pt-L), the energies associated with bond length distortions were calculated using
the Pt-L parameters included in the program (see Appendix). Three meso isomers: meso-l-PtL2,
erythro-8-PtL2 and erythro-9-PtL2 with different leaving groups, L = I-, CI- and SO42- were selected.
These three compounds were tested and they showed estrogen affinity and activity [18]. The
curves obtained are given in Fig..4. For the studied compounds the energy minima were found at
Pt-I = 2.95 A, (C), Pt-CI = 2.55 A, (B) and Pt-O = 2.1 A, (A)). However, the obtained Pt-I bond
length value is higher than the e.xperimental one reported for erythro-8-Ptl2 (2.566 A, 2.574 A) and
erythro-9-Ptl2 (2.583 A, 2.586 A), (Table I)o[18]. The calculated Pt-CI bond length at the energy
minimum is also higher than the value 2.31 A in related compound meso-3-PtCI2 [21].
The Pt-O bond length value is not known and comparison is not possible. The E vs. r(Pt-L)
plots are drawn for a wide range of possible r values (1.4 3.8 A). It is seen from theFig. 4 that
irrespective of the leaving group, the order of the energies at the minima is as follows:
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meso-l-PtL < erythro-8-PtL < erythro-9-PtL
-1.22 < 4.16 < 6.78 kcal mol-1 Ptl=
O. 14 < 5.45 < 8.17 kcal mol- PtCl=
34.52 < 39.38 < 43.33 kcal mol- PtS04
The same energy order was found for the entire range of studied r values although the
energy differences become smaller when moving away from the minima.
From Fig. 4 one may conclude that the shape of all curves is almost independent of the
type of the leaving group: the curves are shifted in E and r, but the curvature (a measure of the
force constant for Pt-L) is almost the same (MM uses generic values for the three cases).
Complexes with leaving group I. The energy order, thus obtained, meso-l-Ptl < erythro-8-Ptl= <
erythro-9-Ptl, is not exactly reverse to the known estrogen activity order [18], meso-l-Ptlz>
erythro-9-Ptl > erythro-8-Ptlz
The complex with the lowest energy (meso-l-Ptl2) has the highest activity. At the same
time the energy order for the erythro species: erythro-8-Ptl= < erythro-9-Ptlz does not correlate
reversibly with the known activity. However, this energy order was obtained with equal Pt-I bond
distances for erythro-8-Ptlz and erythro-9-Ptl=, namely Pt-1=2.670 A (included in the database, see
Appendix).
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Fig 4 The energy (E) the bo Pt-L): (A)- a ngth r( L=SO,Z-, meso-l-PtSO,, a-
erythro-8-PtSO,, a- erythro-9-PtSO4, (B)- L=CI-, b meso-l-PtCl=, b- erythro-8-PtClz, b-
erythro-9-PtCI2, (C)- L=I-, cl- meso-l-Ptl2, c2-erythro-8-Ptl2, c3- erythro-9-Ptl2.
A survey of the X-ray data in Table shows that erythro-8-Ptl2 has shorter Pt-I distances than those
of erythro-9-Ptl=. Since the MM energy of erythro-8-Ptl is slightly lower in value as compared with
that of erythro-9-Ptl_ we expected that the energy order erythro-8-Ptl < erythro-9-Ptlz may be
reversed when the real distances are taken into account. Thus, the geometry optimization of
erythro-8-Ptlz and erythro-9-Ptl was done with available X-ray data for Pt-N, Pt-I bond lengths and
I-Pt-I, N-Pt-N bond angles (Table I)[18].
The other geometry parameters do not differ significantly from those included in the MM
database (see Appendix). However, X-ray data are not available for the other complexes in this
group: meso-l-Ptlz, erythro-5-Ptl and erythro-7-Ptlz. In these cases parameters close to those for
erythro-9-Ptlz were used in the geometry optimization. The reason to use these parameters is that
the complexes with unknown structure have CI substituents in 2 positions of the Ph rings as it is in
erythro-9-Ptl (with the exception of erythro-5-Ptl).
The complexes were modelled by constraining Pt in the plane of the ligand donor atoms.
The calculated bond lengths and bond angles are compared with the experimental values for
erythro-8-Ptlz and erythro-9-Ptl in Table I. Within the constraints used in the calculations the
experimental bond lengths and bond angles are reproduced quite well by MM calculations.
Complexes with leaving group CI. The complexes with leaving group L = CI were treated in the
same way as those with L I. Since X-ray diffraction data for this group of complexes are not
available we used the Pt-CI and Pt-N bond lengths and the CI-Pt-CI and N-Pt-N bond angles for
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meso-3-PtCl (X = OH, Y = Z H), namely r(Pt-CI) = 2.31 A, r(Pt-N) = 2.07 A, <CI-Pt-CI 92.4,
<N-Pt-N = 81.2 and <N-Pt-CI 93.3 [21,24]. The results thus obtained follow the trends already
obtained for the Ptl complexes. The MMX energy order: meso-l-PtCl < erythro-9-PtCl < erythro-
8-PtCI= (which correlates reversibly with the estrogen activity order) was obtained when shorter Pt-
L bond lengths (Zv--_0.02 A) are assumed for the erythro-8-PtCl as compared with the erythro-9-
PtCI= (as for Ptl= complexes). When optimization was carried out without shortening the Pt-L bond,
the order: erythro-8-PtCl= < erythro-9-PtCl=was obtained. The meso-l-PtCl= has always the lowest
energy.
Table I. MMX energies and structural parameters (calculated and experimental) for erythro-8-Ptl=
and erythro-9-Ptl=.
Complex erythro-8-Ptl,(5 conformer erythro-9-Ptl, X conformer
calc. exp. [16] calc. exp.[16]
(this work) (this work)
MMXE(kcal mol-) 74.39 71.82
r(Pt-I) (ang) 2.566 2.566(2) 2.584 2.583(2)
r(Pt-lJ (ang) 2.579 2.574(2) 2.586 2.586(2)
r(Pt-N) (ang) 2.078 2.09(1) 2.123 2.05(1)
r(Pt-NJ (ang) 2.115 1.96(1) 2.167 2.08(1)
/(l-Pt-I (deg) 94.64 94.15(7) 94.39 94.59(4)
Z(N-Pt-NJ (deg) 82.73 82.10(4) 81.50 82.1(4)
Z(I-Pt-N) (deg) 93.04 93.70(4) 93.14 91.9(3)
Z(Iz-Pt-NJ (deg) 89.58 90.0(3) 90.97 90.2(3)
Z(I-Pt-NJ (deg) 175.73 175.5(4) 174.51 175.1(3)
Z(Iz-Pt-N) (deg) 172.24 171.8(4) 172.47 173.1(3)
/-(N-C-C2-N2) (deg)
/(N-Pt-N-C) (cteg)
_/(N-Pt-Nz-CJ (deg)
A(N-C-C-C) (deg)
/-(N-C--C)
54.35 51.90 -50.53 -51.50
19.46 17.79 -24.57 -12.45
10.01 12.35 -2.21 16.37
-146.62 -141.70 145.19 150.04
149.67 151.68 37.51 41.81
d(O-O) (ang) 8.40 8.10 8.27 7.80
Complexes with leaving group S02-. The complexes with L SO42- were optimized in the same
way. No X-ray diffraction data are available for this group of complexes and for this reason
parameters from the MM2 database were used. The question whether water-containing
(ethylenediamine) (sulfato)platinum(ll) complexes exist as unidentate aqua (ethylenediamine)
(sulfato)platinum(ll) complexes (Fig. 5a) or as diaqua (ethylenediamine) platinum(ll)sulfates (Fig.
5d) was decided in favour of the Rochon and Melanson structure (Fig. 5a) by X-ray diffraction [22]:
in (N, N-dimethylenediamine) (sulfato) platinum(ll) complexes with 2 HO molecules, the sulfate ion
is a unidentate ligand and another site in the coordination sphere of Pt is occupied by HO.
The antitumor activity of the (ethylenediamine) (sulfato)platinum(ll) complexes is not
affected by differences in structures (a) and (d), since in aqueous solutions the sulfato group from
the unidentate structure (a)in (ethylenediamine)(sulfato)platinum(ll) complexes is quickly replaced
by HO molecules, thus forming the active diaqua(ethylenediamine)platinum(ll)ion (d) [22].
All complexes in this group were modelled as unidentate monoaqua (ethylenediamine)
(sulfato)platinum(ll) complexes (L = SO42- and L HO).
The energy order obtained at the minima of the E vs.r(Pt-OSO) correlation curves is:
meso-l-PtSO4 < erythro-8-PtSO4 < erythro-9-PtSO4.
Unfortunately, X-ray data for Pt-O bond distances are not available and we do not know
how far from the theoretical minimum (rpt.o = 2.1 =) are the experimental bond lengths. In order to
obtain the energy order erythro-9-PtSO4 < erythro-8-PtSO4, a shorter (as compared with 2.1 =,
obtained at the minimum) Pt-O bond distance (rpt_o = 1.9 =) in erythro-8-PtSO4was used.
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B. Influence of the type and the positions of the ring substituents on the calculated
energies and the estrogen activities (Table II)
SO3
<Pt SO
/<so
b
2+
d
Fig. 5. Structures of water-containing (ethylenediamine)(sulfato)platinum(ll) complexes: a
unidentate monoaqua(ethylenediamine)(sulfato)platinum(ll), b,c bidentate (ethylene-
diamine)(sulfato)platinum(ll), d unidentate diaqua(ethylenediamine)(sulfato)platinum(ll) [12]
Table II. MMX energies (in kcal mol-) for meso-l-PtL2, erythro-5-PtL2, erythro-7-PtL2, erythro-8-
PtL2 and erythro-9-PtL2 (L = I-, CI-, SO,2-).
Complex meso-:k meso-5 d, I-5 d, I-X
meso- 1 -Ptl 67.56 68.40 71.05 65.87
erythro-5-Ptl 77.55 77.81 77.49 76.06
erythto-7-Pt 70.08 70.27 73.74 68.26
erythro-8-Ptl 75.65 74.39 74.12 76.07
erythro-9-Ptl 71.82 72.39 73.99 71.77
meso- -PtCI 32.37 32.81 32.57 30.59
erythro-5-PtCl 41.63 42.15 39.41 40.82
erythro-7-PtC 12 34.49 34.89 34.95 32.96
erythro-8-PtC 12 39.56 39.20 38.58 38.43
erythro-9-PtC 12 36.28 36.47 35.72 36.37
meso- 1-PtSO 34.52 34.81 36.64 30.68
erythro-5-PtSO, 44.09 44.41 41.06 40.74
erythro-7-PtSO, 36.84 37.02 38.19 32.76
erythro-8-PtSO 40.94 41.17 40.32 37.07
erythro-9-PtSO, 39.04 38.90 39.69 36.46
Recently we have studied in details the influence of the type of the ring substituents (CI, F
and OH) and their positions in the phenyl rings (2, 3, 4, 5 and 6) on the calculated energies and
thermodynamic stabilities of the studied compounds [26]. Here we will present only an essential
part of the results.
Complexes with leaving group I. The calculated MMX energies for the complexes with leaving
group are given in Table II (see also [26]).
Meso-l-Ptl2. Meso-l-Ptl2 (four CI substituents in 2- and 6-positions of the aromatic rings)
was with the lowest energy (67.56 kcal mol-1) in the studied series of meso isomers. This complex
has the highest estrogen activity among all the tested compounds of this group [18]. The
calculated energies for all the studied compounds follow the order:
meso-1-Ptl2 < erythro-7-Ptl2 < erythro-9-Ptl2 < erythro-8-Ptl2 < erythro-5-Ptl2.
Erythro-9-Ptl and erythro-8-Ptl. Erythro-9-Ptl and erythro-8-Ptl= have also shown
estrogen properties and the estrogen activity order: meso-l-Ptl > erythro-9-Ptlz > erythro-8-Ptl
[18] follows the energy order we found after taking into account the real bond lengths: meso-l-Ptlz
< erythro-9-Ptl < erythro-8-Ptlz. As seen from Table II the calculated energy order is reversed with
respect to the estrogen activity order; the complex with the lowest energy has the best estrogen
activity (meso-l-PtlJ.
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Erythro-8-Ptl2 and erythro-9-Ptl2 have different X substituents: for erythro-8-Ptl2, X = F and
for erythro-9-Ptl2, X CI (Fig. 2). Four other complexes (obtained by exchanging the X and Y
positions) were included in the calculations [26]. The calculated MMX energies for erythro-8-Ptl2
and erythro-9-Ptl2 are given in Table II1.
The results in Table III show that for erythro-8-Ptl2 the lowest energy isomer is the 5-
conformer, with X F in 2-position of the axial aromatic ring (MMX = 74.39 kcal mol-, Fig. 2c). X-
ray diffraction data reveal that the erythro-8-Ptl2 exists namely as meso isomer in 5 conformation
[18]. All other isomers are with higher energies. At the same time for erythro-9-Ptl2 the lowest
energy conformer is the % conformer, with X=CI in 2-position of the axial aromatic ring
(MMX=71.82 kcal mol-, Fig. 2b). This is again in full agreement with available X-ray and NMR
data which show that erythro-9-Ptl2 exists as meso isomer in :k conformation. These two
complexes, erythro-8-Ptl2 (5-conformer) and erythro-9-Ptl2 (:k-conformer) were tested and they
show antitumor activity against estrogen positive tumors [18]. If we compare the energies of these
two complexes (74.39 and 71.82 kcal mol-) the "preferred" one is erythro-9-Ptl2 (erythro-9-Ptl2 has
higher activity than erythro-8-Ptl2). They are both less active (higher energy) as compared with
meso-l-Ptl2 (67.56 kcal mol-1). Table II1. MMX energies (in kcal mol-) for erythro-8-PtL2 and
erythro-9-PtL2 (L = I-, CI-, SO,2-) with different substituents.
Complex X and Y are X and Y are
in the equatorial ring in the axial ring
erythro-8-Ptl 78.122a 79.49* 74.392c 77.89**
meso-
erythro-8-Ptl 78.872d 78.25* 75.652b 78.78**
meso-X
erythro-9-Ptl= 76.242a 76.99* 72.392c 77.46**
meso-5
erythro-9-Ptl= 74.932d 75.10" 71.822b 76.07**
meso-X
erythro-8-PtCl= 43.072a 42.87* 39,202c 42.45**
meso-
erythro-8-PtCl 42.192d 42.01" 39.562b 42.79**
meso-
erythro-9-PtCl 38.782a 39.30* 36.472c 40.08**
meso-5
erythro-9-PtCl 39.532d 39.58* 36.292b 40.17**
meso-X
erythro-8-PtSO 43.392a 42.98* 41.172c 43.67**
meso-
erythro-8-PtSO 43.932d 43.79* 40.952b 43.84**
meso-X
erythro-9-PtSO4 41.692a 41.77" 38.902c 43.51"*
meso-5
erythro-9-PtSO 41.822d 41.95" 39.042b 42.45**
meso-k
2a, 2d energies of the 2a and 2d species (Fig.2a and Fig. 2d); X (CI or F)
is in 2-position;
energies of the 2a and 2d species obtained after exchange of the X and Y positions, X (CI or F)
is in 6-position;
2b, 2c. energies of the 2b and 2c species (Fig.2b and Fig. 2c); X (CI or F)
is in 2-position;
energies of the 2b and 2c species obtained after exchange of the X and Y positions, X (CI or F)
is in 6-position.
The results in Table III show also the following trends:
(i) when the X and Y substituents are in an equatorial aromatic ring (Fig. 2a and 2d) the
exchange of their positions does not influence significantly the calculated MMX energies (compare
first and second columns of Table III).
(ii) when the X and Y substituents are in the axial aromatic ring (Fig. 2b and 2c) the
exchange of their positions increases the calculated energies (compare third and fourth columns of
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Table III). Obviously, the "preferred" complexes are those with substituents in the axial ring and CI
(F) atom in 2-position of the aromatic ring. In the case of erythro-8-Ptl this is the 5-conformer and
in the case of erythro-9-Ptl this is the X-conformer (both were prepared also experimentally).
Erythro-7-Ptl.. Erythro-7-Ptl has also a low energy (MMX =70.08 kcal mol-) as compared
with meso-l-Ptl (see the first column of Table II). This complex, however, has no estrogen activity.
This finding was explained by the absence of OH- substituent in para-position which determines
the estrogen properties of the complex. It was accepted that the estrogen receptor of the tumor cell
binds the complexes through H-bonds between two OHs in the aromatic rings and binding sites of
the receptor [7].
Erythro-5-Pl.. Number of CI atoms in the aromatic rings. The low energy of erythro-7-Ptl
(MMX = 70.08 kcal mol-1) is due to the presence of four CI atoms in the aromatic rings as in meso-
1-PtI(MMX 67.56 kcal mol-1). With three CI atoms (erythro-9-Ptl) the energy is higher (71.82
kcal mol-1) and with two (erythro-5-Pl) the energy has the highest value (MMX = 77.55 kcal mol-1)
(Table II). For the complexes with X CI the obtained estrogen activity was the highest one. This
is in agreement with the assumption that the presence of CI in the aromatic rings increases the
lipophilic nature of the compounds improving their binding possibility [18].
d,l-5 and d,I-/1, conformers. The energy order found for the d,l- and d,I-X conformers
(threo) is as follows:
D,L-1-Ptl <Threo-7-Ptl <Threo-9-Ptl <Threo-8-Ptl<Threo-5-Ptl.
This order (third and fourth columns of Table II)is the same as for the meso-5 and meso-X
conformers of the studied complexes.
Comparison of the conformational energies of the four isomers meso-& meso-Z, d,l-5 and
d,l-Z) for every complex. For meso-1- Ptl (D,L-1-Ptl), erythro-7-Ptl (threo-7-Ptl) and erythro-9-Pl
(threo-9-Ptl) the following order was found (1-, 3- and 5 rows in Table II):
d,I-X < meso-X meso-6 < d,l-&
For erythro-5-Ptl (threo-5-Ptl) again the X-conformers are preferred but the order of the 6-
conformers is reverse (2 row in Table II):
d,I-X < meso-X-_- d,l-6= meso-6.
As seen from Table II the d,I-X isomers have lower energies as compared with the meso-X
isomers. For erythro-9-Ptl an d,I-X isomer has also been found but its estrogen activity was
relatively low [7]. This was explained in terms of two factors: (a) the spatial location of the two N
atoms, which was different from that in the meso isomers; (b) the lack of flexibility in the five-
membered chelate ring which hinders the approach of the two Ph rings and O-O distance
decrease as is the case in the meso series [7]. It is possible that these complexes, d,I-X, have
another mechanism of action (a hydrolysis mechanism). Recently, we have shown that the energy
of d,l-3-PtCl, d,I-X, is lower than the energy of the meso-3-PtCl, meso-X, and the rate of
hydrolysis and antitumor activity of the first compound are higher than those of meso-3-PtCl [24].
On the basis of these results, reported elsewhere [24], the hydrolysis mechanism of action may be
assumed for the d,I-X isomer. Obviously, regardless of the mechanism of action, the complexes
used as antitumor agents should be thermodynamically stable and should not undergo kinetic
substitutions in order to reach the cell unchanged and to attack subsequently the critical area of
DNA.
The only compound in this series that preferred the 5 conformation is erythro-8-Ptl:
meso- _= d,l- < meso-X < d,I-X.
The calculated energies are in agreement with the X-ray diffraction data, which reveal
meso isomer in conformation for erythro-8-Ptl and meso isomer in ;L conformation for erythro-9-
Ptl [18].
Complexes with leaving group CI-. The calculated energies are given in Table II and they follow the
order:
meso-l-PtCl < erythro-7-PtCl < erythro-9-PtCl < erythro-8-PtCl < erythro-5-PtCl.
For erythro-8-Ptl and erythro-9-Ptl, four other complexes (obtained after exchanging the
X and Y positions) were included in the calculations. The calculated MMX energies for all
complexes of erythro-8-Ptl and erythro-9-Ptl are given in Table II1.
The results for the complexes with leaving group CI show that: (i) meso-X and meso-5
conformers differ only slightly in energy; (ii) the d,I-X isomers have always lower energies as
compared with both meso isomers.
Complexes with leaving group S02-. The calculated energies for this group complexes follow the
same order (Table II):
meso- 1 -PtSO4<erythro-7-PtSO4<erythro-9-PtSO4<erythro-8-PtSO4<erythro-5-PtSO4.
The results for this group of complexes confirm the trends obtained for the other two
groups (L = Cl and I): (i) the meso-l-PtSO4 has always the lowest energy and erythro-9-PtSO4 <
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erythro-8-PtSO4 for rpt.o 1.9 A; (ii) the d,I-X are preferred for all complexes; (iii). meso-X and
meso-6 conformers differ only slightly in energy. The results for erythro-8-PtSO4 and erythro-9-
PtSO4 complexes are compared in Table III. The exchange of X and Y substituents in the axial ring
increases the energy while the exchange of the substituent positions in the equatorial ring does not
bring significant energy changes.
C. Rotational barriers about Cp "-Car bonds.
In order to obtain the preferred orientations of the aromatic rings the rotational energies,
Erot, about C,3 Car bonds were calculated for all complexes starting from the optimized geometries
and rotating from 0 to 360 deg, with t0 deg increment. The following trends were found’
(A) All complexes have their energy minimum at the starting (optimized) geometries and another
minimum at 180 deg. The second minimum is higher in energy (by 2-10 kcal mol-)as compared
with the energy of the optimized geometry (Erot = 0.0 kcal mol-1). The rotational barriers are
different for the complexes with substituted and unsubstituted (or partially substituted) aromatic
ring:
1. For all meso and d,I-X isomers
a) The rotation about C.3 -Car bonds of the substituted aromatic ring (with four CI substituents in 2-
and 6-positions of the aromatic rings (meso-l-PtL, erythro-7-PtL), is highly unfavorable since the
rotational barriers are very high (>> 100 kcal mol-1).
b) In the case of erythro-8-Ptl= and erythro-9-Ptl= (three CI substituent in 2-or 6-positions) the
barriers obtained are lower in energy (< 100 kcal mol-) but rotation is still unfavorable.
c) In the case of erythro-5-PtL (unsubstituted aromatic ring) the rotational energy about the C-Ca bond of the unsubstituted aromatic ring is 80 kcal mol-1, for d,I isomer and 100 kcal mol-, for
meso isomer.
2. For the d,I isomers in 5 conformation
The d,l-5 conformers have two other minima (at --90 deg and --270 deg ); they are much higher in
energy than the minimum at 180 deg (by 20-70 kcal mol-); these minima are shallow and
obviously not populated. One exception is d,l-5 erythro-5-Ptl= (threo-5-Ptl) where the three minima
for the rotation energy of the unsubstituted aromatic ring have low values (6.30, 0.51 and 4.45 kcal
mol-). This exception was explain in terms of the lack of substituents in one aromatic ring (X Y
H). The calculated rotational barriers (-9 kcal mol-) are lower as compared with the barriers of the
substituted ring and rotation about C,-Ca bond could be possible.
(B) The 2-position of CI or F in the aromatic ring is preferred (Ero = -3.00 kcal mol-) as compared
with the 6-position (Eot = 0.00 kcal mol-).
Conclusions
The results obtained in this work show that:
(a) The MM calculations predict correctly the absolute conformation as found in the solid state by
X-ray diffraction, and hence they can be expected to predict correctly the conformations for which
X-ray diffraction data are not available;
(b) The calculated energies and the stabilities of the studied complexes (meso-l-PtL=, erythro-9-
PtL and erythro-8-PtL) on one side and their estrogen affinity and activity on the other side are
found to run parallel: the most stable complex has the highest estrogen activity. Such trends may
help further the selection of new complexes to test for their biological properties.
(c) The type and the positions of the ring substituents influence the calculated energies. When
the X and Y substituents are in an equatorial aromatic ring, the exchange of their positions does
not influence the calculated MMX energy. Conversely, when the X and Y substituents are in the
axial aromatic ring, the exchange of their positions increases the calculated energies. The
"preferred" complexes and conformations are those with axial ring substituents and CI (or F) atoms
in 2-position of the aromatic ring: the -conformer for erythro-8-Ptl and X-conformer for erythro-9-
Ptl. Both compounds were prepared also experimentally in these conformations.
(d) The type of the leaving group is of minor importance for the calculated energy order and
estrogen activity;
(e) The calculated rotational barriers about the C-C,= bonds when both aromatic rings are
substituted (meso-l-PtL, erythro-7-PtL, erythro-8-PtL, erythro-9-PtL) are very high and rotations
about these bonds are unfavorable. In the case of erythro-5-PtL= (one ring is unsubstituted)
rotation about the C-C.= bond of the unsubstituted aromatic ring is probable since the rotational
barrier is low (-- 9 kcal mol-1).
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Appendix
The MMX force field includes the folowing terms: bond stretch, Er, valence angle
deformation, Ev, cross-term for bond-angle interaction, Er.v, torsional energy, Et, van der Waals
(non-bonded) interactions, Eva,, dipole-dipole interaction, Eee.. Both E and Ev are treated by the
Hook law. Below are given the set of parameters used in this work.
Stretch k (mdyn A-l) Standard bond length (A) bond moment (D)
this work literature this work literature
Pt LP 2.000 0.800
Pt- Cl 2.000 1.4728 2.300 2.3028 0.000
Pt- N 2.000 2.5437b 1.980 2.0337b 0.000
1.6828 2.0028
Pt O 2.000 1.800 0.000
Pt O- 2.000 1.800
N C 5.100 6.0037c, 34 1.440 1.4937c, 34 0.040
C C 4.400 5.0037c, 34 1.523 1.5037c, 34 0.000
4.5028 1.5428
N H 6.100 5.6437c, 34 1.015 0.9137c, 34 -0.760
4.9228 1.0028
C H 4.600 5.0037c, 34 1.113 0.9737c, 34 0.000
4.5528 1.0928
C Car 5.000 5.0034 1.497 1.5034 0.000
Ca- C,r 9.600 1.337 0.000
C, H 4.600 5.0034 1.101 0.9734 -0.200
O H 4.600 5.0034 0.942 0.9134 -1.115
C- O(H) 6.800 1.355 0.000
N LP 4.500 0.600 0.600
O- LP 4.500 0.600 0.900
Bend ke (mdyn A-) Standard Valence angle (deg.)
this work literature this work literature
CI Pt Cl 0.000
CI- Pt- N 0.000
CI- Pt- O 0.000
N Pt- O 0.000
N Pt- N 0.000
Pt- N C 0.000
Pt O H 0.000
N -C -C 0.570
N C Car 1.045
C C Car 0.450
C Car- Car 0.550
Car- Car-. O 0.700
C,r-Cr -C,r 0.430
Pt- N H 0.000
Pt- N LP 0.000
Pt- O LP 0.000
H N H 0.500
H N C 0.500
LP- N C 0.500
N C H 0.500
H C H 0.320
0.00034 0.2829,30,37 90, 120, 180 86.629.30,37
0.00034 0.2829,30,37 90, 120, 180 86.629,30,37
0.00034 90, 120, 180
0.00034 90, 120, 180
0.00034 0.40029,30,37 90, 120, 180 90.029,30,37
0.30037b, 0.28029,30,37 127.337b, 1 10.034
0.20034 109.529,30,37
0.10034 109.734
0.50037c, 0.4534 109.47
110.74
109.47
121.40
124.30
120.00
0.10034 0.2829,30,37 109.70 109.734,109.529,30,37
0.32037c, 0.33034 104.50 108.9834
0.36037c, 0.45034 109.47 109.4934
109.20
0.36037c 108.80 108.9837c
0.32037c 109.40 108.9837c
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C-C-H
C- O LP
LP O LP
LP-O-H
LP-N-H
0.360
0.100
0.240
0.240
0.500
0.36037c, 34
0.45034
109.39 109.3837c
120.00
131.00
101.01
108.00
Torsional
(this work)
Vl V2 V3
N -C-C-N
N C Cr- C,r
C-C-N-LP
Car- C- N LP
-0.400
0.000
0.200
0.000
-1.100
0.000
-0.220
0.000
1.200
0.000
0.100
0.000
Van der Waals R EPS LPD IHTYP
this work literature this work literature
C (sp3)
C (sp2)
H (C- H)
O (C- OH)
N (sp3)
CI
LP
Car
H (OH)
H (NH)
M1
M2
M3
spherical H20
1.900 1.90034 0.044 0.04434
1.940 0.044
1.500 1.44034 0.047 0.02434
1.740 1.70034 0.050 0.05534
1.820 1.80034 0.055 0.05034
2.030 0.240
1.200 0.016
1.900 0.044
1.100 0.036
1.125 0.034
0.000 0.400
0.000 0.400
0.000 0.400
1.530 0.500
0
110
0
90
200
10
0
110
0
0
0
0
0
0
0
0
20
0
0
0
0
0
40
0
0
0
0
0
Out-of-plane bending (this work)
C Car 0.800
Car- Car 0.800
C O 0.800
Stretch Bend (this work)
Str.-bend (1) 0.12
Str.-bend (2) 0.25
Str.-bend (3) 0.09
Str.-bend (4) -0.40
For explanation of the abbreviations used in this Table see [39].
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